Evidence supporting the use of: Cannabigerol
For the health condition: Dermatitis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cannabigerol (CBG) is a non-psychoactive cannabinoid found in the Cannabis sativa plant. Recent preclinical research has explored its possible benefits for inflammatory skin conditions such as dermatitis. In vitro studies have demonstrated that CBG possesses anti-inflammatory, antibacterial, and antioxidant properties. For example, a study published in 2020 (Oláh et al., Experimental Dermatology) showed that CBG could reduce inflammation in human keratinocyte cell cultures by decreasing the release of pro-inflammatory cytokines. Additionally, CBG has demonstrated inhibitory effects on certain skin pathogens, such as Staphylococcus aureus, which are often implicated in the exacerbation of dermatitis.

Despite these promising findings, the evidence remains limited to laboratory and animal models. To date, there are no published clinical trials directly evaluating the efficacy or safety of topical or systemic CBG in human patients with dermatitis. While some cosmetic and wellness products include CBG for skin health, these are not supported by robust clinical data. Therefore, while initial scientific investigations provide a rationale for further study, the current level of evidence supporting CBG’s use in dermatitis is preliminary and cannot be considered conclusive or sufficient for medical recommendations.

More about Cannabigerol
More about Dermatitis

Products containing Cannabigerol

We currently have no products on Vitabase that contain this ingredient.